Trilogy Capital Inc. Dexcom Inc Transaction History
Trilogy Capital Inc.
- $1.92 Billion
- Q3 2024
A detailed history of Trilogy Capital Inc. transactions in Dexcom Inc stock. As of the latest transaction made, Trilogy Capital Inc. holds 6,867 shares of DXCM stock, worth $553,274. This represents 0.02% of its overall portfolio holdings.
Number of Shares
6,867
Previous 16,287
57.84%
Holding current value
$553,274
Previous $1.85 Million
75.08%
% of portfolio
0.02%
Previous 0.1%
Shares
7 transactions
Others Institutions Holding DXCM
# of Institutions
1,014Shares Held
351MCall Options Held
5.51MPut Options Held
5.6M-
Vanguard Group Inc Valley Forge, PA47.4MShares$3.82 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY34.5MShares$2.78 Billion0.09% of portfolio
-
Capital Research Global Investors Los Angeles, CA17.9MShares$1.45 Billion0.26% of portfolio
-
State Street Corp Boston, MA16.7MShares$1.34 Billion0.05% of portfolio
-
Baillie Gifford & CO15MShares$1.21 Billion0.77% of portfolio
About DEXCOM INC
- Ticker DXCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 386,257,984
- Market Cap $31.1B
- Description
- DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...